Jacob Shery, Rao Rekha, Gorain Bapi, Boddu Sai H S, Nair Anroop B
Department of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman P.O. Box 4184, United Arab Emirates.
Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India.
Pharmaceutics. 2025 Aug 21;17(8):1079. doi: 10.3390/pharmaceutics17081079.
Phytochemicals exhibit a broad spectrum of pharmacological activities, including significant anticancer potential. However, their clinical translation is often hampered by poor aqueous solubility, low bioavailability, and chemical instability. Lipid-based nanocarriers, especially solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), have proven to be effective strategies for addressing these challenges. These nanocarriers improve the solubility, stability, and bioavailability of phytochemical-based anticancer agents, while enabling controlled and tumor-specific drug release. Encapsulation of anticancer phytochemicals such as curcumin, quercetin, resveratrol, silymarin, and naringenin in SLNs and NLCs has demonstrated improved therapeutic efficacy, cellular uptake, and reduced systemic toxicity. Co-delivery strategies, combining multiple phytochemicals or phytochemical-synthetic drug pairs, further contribute to synergistic anticancer effects, dose reduction, and minimized side effects, particularly important in complex cancers such as glioblastoma, breast, and colon cancers. This review presents a comparative overview of SLNs and NLCs in terms of formulation methods, in vitro characterization, and classification of key phytochemicals based on chemical structure and botanical sources. The roles of these lipidic carriers in enhancing anticancer activity, challenges in formulation, and recent patent filings are discussed to highlight ongoing innovations. Additionally, hybrid lipid-polymer nanoparticles are introduced as next-generation carriers combining the benefits of both systems. Future research should aim to develop scalable, biomimetic, and stimuli-responsive nanostructures through advanced surface engineering. Collaborative interdisciplinary efforts and regulatory harmonization are essential to translate these lipid-based carriers into clinically viable platforms for anticancer phytochemical delivery.
植物化学物质具有广泛的药理活性,包括显著的抗癌潜力。然而,它们的临床转化常常受到水溶性差、生物利用度低和化学稳定性差的阻碍。基于脂质的纳米载体,尤其是固体脂质纳米粒(SLNs)和纳米结构脂质载体(NLCs),已被证明是应对这些挑战的有效策略。这些纳米载体提高了基于植物化学物质的抗癌药物的溶解度、稳定性和生物利用度,同时实现了可控的肿瘤特异性药物释放。将姜黄素、槲皮素、白藜芦醇、水飞蓟宾和柚皮素等抗癌植物化学物质封装在SLNs和NLCs中已显示出提高了治疗效果、细胞摄取并降低了全身毒性。联合递送策略,即将多种植物化学物质或植物化学物质与合成药物组合使用,进一步有助于产生协同抗癌作用、降低剂量并将副作用降至最低,这在胶质母细胞瘤、乳腺癌和结肠癌等复杂癌症中尤为重要。本综述对SLNs和NLCs在制剂方法、体外表征以及基于化学结构和植物来源的关键植物化学物质分类方面进行了比较概述。讨论了这些脂质载体在增强抗癌活性方面的作用、制剂方面的挑战以及最近的专利申请情况,以突出正在进行的创新。此外,还介绍了脂质 - 聚合物杂化纳米粒作为结合了两种系统优点的下一代载体。未来的研究应旨在通过先进的表面工程开发可扩展、仿生和刺激响应性的纳米结构。跨学科的合作努力和监管协调对于将这些基于脂质的载体转化为用于抗癌植物化学物质递送的临床可行平台至关重要。